PMID- 36478054
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230324
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 44
IP  - 2
DP  - 2023 Jan 7
TI  - Polygenic risk scores for the prediction of cardiometabolic disease.
PG  - 89-99
LID - 10.1093/eurheartj/ehac648 [doi]
AB  - Cardiometabolic diseases contribute more to global morbidity and mortality than 
      any other group of disorders. Polygenic risk scores (PRSs), the weighted 
      summation of individually small-effect genetic variants, represent an advance in 
      our ability to predict the development and complications of cardiometabolic 
      diseases. This article reviews the evidence supporting the use of PRS in seven 
      common cardiometabolic diseases: coronary artery disease (CAD), stroke, 
      hypertension, heart failure and cardiomyopathies, obesity, atrial fibrillation 
      (AF), and type 2 diabetes mellitus (T2DM). Data suggest that PRS for CAD, AF, and 
      T2DM consistently improves prediction when incorporated into existing clinical 
      risk tools. In other areas such as ischaemic stroke and hypertension, clinical 
      application appears premature but emerging evidence suggests that the study of 
      larger and more diverse populations coupled with more granular phenotyping will 
      propel the translation of PRS into practical clinical prediction tools.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      European Society of Cardiology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - O'Sullivan, Jack W
AU  - O'Sullivan JW
AUID- ORCID: 0000-0003-3629-2546
AD  - Stanford Center for Inherited Cardiovascular Disease, Stanford University School 
      of Medicine, Stanford, CA, USA.
AD  - Division of Cardiology, Department of Medicine, Stanford University School of 
      Medicine, Stanford, CA, USA.
FAU - Ashley, Euan A
AU  - Ashley EA
AUID- ORCID: 0000-0001-9418-9577
AD  - Stanford Center for Inherited Cardiovascular Disease, Stanford University School 
      of Medicine, Stanford, CA, USA.
AD  - Division of Cardiology, Department of Medicine, Stanford University School of 
      Medicine, Stanford, CA, USA.
AD  - Department of Genetics, Stanford University School of Medicine, Stanford, CA, 
      USA.
FAU - Elliott, Perry M
AU  - Elliott PM
AUID- ORCID: 0000-0003-3383-3984
AD  - UCL Institute of Cardiovascular Science, Gower Street, London WC1E 6BT, UK.
AD  - St. Bartholomew's Hospital, W Smithfield, London EC1A 7BE, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/epidemiology/genetics
MH  - *Brain Ischemia
MH  - *Stroke
MH  - Risk Factors
MH  - *Coronary Artery Disease/epidemiology/genetics
MH  - *Hypertension/epidemiology/genetics
MH  - *Atrial Fibrillation
MH  - Genetic Predisposition to Disease/genetics
MH  - Genome-Wide Association Study
OTO - NOTNLM
OT  - Genetics
OT  - Polygenic risk scores
OT  - Precision Medicine
COIS- Conflict of interest: JOS is an advisor to Google Health AI. E.A. is founder of 
      Personalis, DeepCell, Svexa; advisor to Pacific Biosciences, SequencBio, and 
      Apple and non-executive director of AstraZeneca. PE reports consulting fees from 
      Pfizer, Sanofi Genzyme, Sarepta, Freeline, Bristol Myers Squibb.
EDAT- 2022/12/09 06:00
MHDA- 2023/01/11 06:00
CRDT- 2022/12/08 12:33
PHST- 2021/12/08 00:00 [received]
PHST- 2022/08/28 00:00 [revised]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/12/08 12:33 [entrez]
AID - 6880614 [pii]
AID - 10.1093/eurheartj/ehac648 [doi]
PST - ppublish
SO  - Eur Heart J. 2023 Jan 7;44(2):89-99. doi: 10.1093/eurheartj/ehac648.